T2 Biosystems (NASDAQ:TTOO) will be releasing its earnings data after the market closes on Thursday, May 6th. Analysts expect T2 Biosystems to post earnings of ($0.07) per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

T2 Biosystems (NASDAQ:TTOO) last posted its earnings results on Wednesday, March 3rd. The medical equipment provider reported ($0.07) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.07). The business had revenue of $7.79 million for the quarter, compared to analyst estimates of $7.78 million. On average, analysts expect T2 Biosystems to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

NASDAQ TTOO opened at $1.38 on Tuesday. The company has a market capitalization of $204.92 million, a PE ratio of -2.00 and a beta of 0.72. The company has a fifty day moving average of $1.54 and a 200 day moving average of $1.65. T2 Biosystems has a 1 year low of $0.48 and a 1 year high of $3.79. The company has a debt-to-equity ratio of 2.54, a current ratio of 4.97 and a quick ratio of 4.63.

A number of research analysts recently issued reports on the stock. Alliance Global Partners decreased their target price on shares of T2 Biosystems from $2.40 to $1.65 and set a “neutral” rating for the company in a research report on Friday, March 5th. Jonestrading reaffirmed a “buy” rating and issued a $3.50 price objective on shares of T2 Biosystems in a report on Wednesday, January 27th. Canaccord Genuity reaffirmed a “buy” rating and issued a $3.50 price objective on shares of T2 Biosystems in a report on Tuesday, January 26th. Finally, SVB Leerink cut their price objective on shares of T2 Biosystems from $4.00 to $3.00 and set an “outperform” rating for the company in a report on Wednesday, January 27th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $2.44.

About T2 Biosystems

T2 Biosystems, Inc, an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance technology that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine.

Featured Article: What is the QQQ ETF?

Earnings History for T2 Biosystems (NASDAQ:TTOO)

Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.